my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
21-01-2010: An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression.
Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS) is a unique project, bringing together top scientists from academic institutions with a wide range of expertise, and partnering them with nearly all major global drugs companies including AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Orion, Pfizer, Roche, Servier and Wyeth.
Other academic institutions involved are: Karolinska Institutet (Sweden), The University of Cambridge (United Kingdom), Central Institute of Mental Health (Germany), CSIC (Spain), the University of Manchester (United Kingdom) and the Bar Ilan University (Israel). A further two pharmaceutical small and medium-sized enterprises (SME), deCODE (Iceland) and Psynova (United Kingdom) will contribute to the success of NEWMEDS, while the SME GABO:mi (Germany) will be managing the project.
With a wealth of new knowledge and research findings related to schizophrenia and depression emerging every year, it has been hard to take these findings from the bench to the clinic. The researchers believe there to be three major bottlenecks that are holding the field back: a lack of accurate animal models to guide the drug discovery, a lack of tools and tests in healthy volunteers that can provide early indication of efficacy; and the reliance of clinical trials on symptom-based Diagnostic and Statistical Manual categories which inevitably leads to biologically heterogeneous groups of patients. NEWMEDS aims to overcome these limitations with a novel approach to drug discovery and strong collaboration within the consortium.
The main objective of NEWMEDS is to develop new models and methods to enable novel treatments for schizophrenia and depression. The project will focus on developing new animal models which use brain recording and behavioural tests to identify innovative and effective drugs for schizophrenia. The project will develop the hardware and analysis techniques to apply brain imaging, especially MRI and PET imaging to drug development. It will examine how new genetic findings (duplication and deletion or changes in genes) influence the response to various drugs and whether this information can be used to choose the right drug for the right patient. And finally, it will try and develop new approaches for shorter and more efficient trials of new medication – trials that may require fewer patients and give faster results.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Oxford BioMedica Announces Lentiviral Vector Development and Manufacturing Collaboration
Oxford BioMedica plc announced that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology. Under the terms of the agreement, Oxford BioMedica will also provide certain process development services ... more
Evotec receives Milestone in Drug Discovery Collaboration
Evotec AG announced that it has received a pre-clinical milestone from its Drug Discovery Collaboration with Novartis. No financial details were given. Under the terms of the agreement, Evotec is responsible for progressing the program up to pre-clinical development and Novartis will then h ... more
Novartis and the University of Pennsylvania (Penn) announced an exclusive global collaboration to research, develop and commercialize targeted chimeric antigen receptor (CAR) immunotherapies for the treatment of cancers. In addition, the parties will jointly establish a new research and dev ... more
We focus on the well-being of companion animals and the health and productivity of farm animals. Our extensive product range provides solutions for the prevention and treatment of various widespread animal diseases and parasite infestations. The majority of these products are available by p ... more
Galapagos delivers candidate drug in osteoarthritis alliance with Servier
Galapagos NV announced that it has identified the first pre-clinical candidate compound in its osteoarthritis alliance with Servier. The compound inhibits a novel mechanism of action discovered by Galapagos. This achievement triggered an undisclosed milestone payment to Galapagos. In July ... more
Servier and Galapagos initiate strategic alliance for innovative treatments in oncology
Servier and Galapagos NV announced that they have entered into a multi-year strategic alliance to develop new cancer therapies. The alliance builds on a combination of novel Galapagos and Servier targets in oncology. Galapagos will be responsible for the discovery and development of new c ... more
Hybrigenics and Servier announced that they have signed a licence and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics will identify and ... more
Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer’s Disease Program
Selvita S.A. announced that its collaboration with Orion Corporationon SEL103 program, for the symptomatic treatment of Alzheimer’s disease has reached the main research milestone and that the jointly discovered molecules from two different chemical families will progress into further pre-c ... more
Orion receives positive CHMP opinion for new intensive care sedative, dexdor® (dexmedetomidine)
Orion Corporation has received information that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of marketing authorisation for dexdor® (dexmedetomidine), a new intensive care sedative.T ... more
Selvita And Orion Pharma Will Collaborate on SEL103 - Alzheimer’s Disease Program
Selvita sp. z o.o. and Orion Corporation from Espoo, Finland announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita’s proprietary program for the treatment of Alzheimer’s disease and other cognitive disorders. Selvita will be respon ... more
Orion Diagnostica Oy is a biomedical company belonging to the Orion Group, the leading health-care company in Finland. Established in 1974, Orion Diagnostica specialises in rapid and easy-to-use clinical diagnostic and hygiene-monitoring products aimed at enhancing the quality and effective ... more
Orion Corporation is dedicated to treating and preventing disease by discovery and developing innovative medicinal treatments. In 2006, Orion Corporation generated sales of EUR 641.1 million, invested EUR 84.1 million in research and development and employed approximately 3,060 people. Orio ... more
Priaxon enters collaboration with GSK on Protein-Protein-Interactions
Priaxon announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modul ... more
Prosensa has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055 ... more
KineMed Announces Biomarker Discovery Collaboration with GSK
KineMed, Inc. announced a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK. The collaboration will seek to identify, optimize and validate novel biomarkers that would enable ... more
Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched
An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression. Novel Methods leading to N ... more
Ablynx announced that it has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $4 million has been triggered by the initiation by Wyeth of a first Phase II multiple dose study in patients with rheumatoid ... more
Biotie Reaches Milestone in Wyeth Collaboration
Biotie announced that it has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a USD 1.0 million milestone payment to Biotie. Timo Veromaa, President and CEO of Biotie said "We are pleased with t ... more
Wyeth improves the lives of millions of people around the world with its outstanding products. And new, innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines and biotechnology, Wyeth is exploring more than 60 new therapies for ... more
Wyeth improves the lives of millions of people around the world with its outstanding products. And new, innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines and biotechnology, Wyeth is exploring more than 60 new therapies for ... more
Wyeth improves the lives of millions of people around the world with its outstanding products. And new, innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines and biotechnology, Wyeth is exploring more than 60 new therapies for ... more
Lilly Announces Withdrawal of Xigris Following Recent Clinical Trial Results
Eli Lilly and Company announced withdrawal of its Xigris® [drotrecogin alfa (activated)] product in all markets following results of the PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in pa ... more
Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases
Eli Lilly and Company announced today a $30 million commitment over five years to fight the rising burden of non-communicable diseases in developing nations. Lilly is launching The Lilly NCD Partnership, which combines the company's unique resources with the expertise of leading global heal ... more
QIAGEN to develop new companion diagnostic for compound in clinical trials for blood cancers
QIAGEN announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement w ... more
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first in class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in I ... more
Mammograms reveal response to common cancer drug
Researchers at Karolinska Institutet have developed a method for assessing the effect of tamoxifen, a common drug to prevent the relapse of breast cancer. The key lies in monitoring changes in the proportion of dense tissue, which appears white on a mammogram, during treatment. Women who sh ... more
New light shed on early stage Alzheimer's disease
The disrupted metabolism of sugar, fat and calcium is part of the process that causes the death of neurons in Alzheimer's disease. Researchers from Karolinska Institutet have now shown, for the first time, how important parts of the nerve cell that are involved in the cell's energy metaboli ... more
Particular DNA changes linked with prostate cancer development and lethality
A new analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer, and that patients with two of these DNA changes have a high likelihood of dying from the disease. Published online in CANCER, the study provides valuable inf ... more
Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched
An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression. Novel Methods leading to N ... more
Scientists present the largest-to-date genetic snapshot of Iceland 1000 years ago
Scientists at deCODE genetics have completed the largest study of ancient DNA from a single population ever undertaken. Analyzing mitochondrial DNA, which is passed from mother to offspring, from 68 skeletal remains, the study provides a detailed look at how a contemporary population differ ... more
deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer
Scientists at deCODE genetics reported the discovery of common versions of two single-letter variations in the human genome (SNPs) that confer risk of basal cell carcinoma (BCC). Unlike the four sets of SNPs previously found by deCODE to confer risk of BCC and cutaneous melanoma, those are ... more
deCODE is a biopharmaceutical company applying its discoveries in human genetics to develop drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health ... more
Genmab Reaches Second Milestone in Lundbeck Collaboration
Genmab A/S announced it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders ... more
Genmab announces progress with Lundbeck collaboration
Genmab A/S announced it had reached the first pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the first milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders o ... more
Lundbeck and Proximagen Sign Strategic Partnership Agreement
H. Lundbeck A/S and Proximagen Group plc announced that they have entered into a Strategic Partnership Agreement. The Agreement is designed to formalise a partnership between the two companies, a partnership in which Lundbeck and Proximagen will jointly apply their expertise in CNS drug d ... more
Lundbeck Pharmaceuticals Italy S.p.A. (LUPI)
Lundbeck Pharmaceuticals Italy is an FDA inspected manufacturer of proprietary APIs and cGMP intermediates for the pharmaceutical, veterinary and life science industries. All our products are manufactured under cGMP's. LUPI offers contract manufacturing services to many large multinati ... more
SFJ Pharmaceuticals and Pfizer to co-develop dacomitinib as treatment for non-small cell lung cancer
The SFJ Pharmaceuticals Group (SFJ), announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial of Pfizer’s investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804). The tria ... more
Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.Under the agreement, Pfizer will provide full funding for the research costs and have the exclusive rig ... more
Ablynx regains rights from Pfizer to nanobodies targeting TNF-alpha
Ablynx announced that it has regained worldwide rights from Pfizer Inc. to develop and commercialise Nanobodies targeting TNF-alpha. These rights include the product ATN-103, for which positive proof-of-concept data from a Phase II trial in rheumatoid arthritis (RA) were announced in May of ... more
New genes for short-sightedness identified
An international team of scientists led by King's College London has discovered 24 new genes that cause refractive errors and myopia (short-sightedness). Myopia is a major cause of blindness and visual impairment worldwide, and currently there is no cure. These findings reveal genetic cause ... more
Scientists shed new light on link between 'killer cells' and diabetes
Killer T-cells in the human body which help protect us from disease can inadvertently destroy cells that produce insulin, new research has uncovered. The study provides the first evidence of this mechanism in action and could offer new understanding of the cause of Type 1 diabetes.Professor ... more
Twin study reveals epigenetic alterations of psychiatric disorders
In the first study to systematically investigate genome-wide epigenetic differences in a large number of psychosis discordant twin-pairs, research at the Institute of Psychiatry (IoP) at King's College London provides further evidence that epigenetic processes play an important role in neur ... more
King's College London King's College London is one of the top 25 universities in the world (Times Higher Education 2009) and the fourth oldest in England. A research-led university based in the heart of London, King's has more than 21,000 students from nearly 140 countries, and more than 5, ... more
FDA clears Roche's vitamin D laboratory test
Roche announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated vitamin D test for use on cobas modular platforms, further expanding the company’s bone metabolism test menu. Vitamin D is an important building block for human health and i ... more
Savira pharmaceuticals GmbH, a spin-off of the European Molecular Biology Laboratory (EMBL), has signed a collaboration and license agreement with Roche, thus further strengthening the links between fundamental research and major pharmaceutical development companies.This partnership should ... more
Roche Steps Back from Illumina Acquisition
F. Hoffman-La Roche dropped its bid to buy Illumina after Illumina’s shareholders made it clear at the company’s annual meeting that the terms were inadequate. Roche had made a $51 per share tender offer for San Diego-based Illumina, but allowed the offer to expire. GlobalData analyzed the ... more
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche i ... more
Environmental factors determine whether immigrants are accepted by cooperatively breeding animals
Cichlid fish are more likely to accept immigrants into their group when they are under threat from predators and need reinforcements, new research shows. The researcher suggests that there are parallels between cooperatively breeding fish's and humans' regulation of immigrants. The Princess ... more
Avian flu viruses which are transmissible between humans could evolve in nature
Avian flu viruses which are transmissible between humans could evolve in natureResearch provides insight into feasibility of virus becoming airborne transmissibleIt might be possible for human-to-human airborne transmissible avian H5N1 influenza viruses to evolve in nature, new research has ... more
Cambridge Team First to Grow Smooth Muscle Cells from Patient Skin Cells
A Cambridge University research team has for the first time discovered a method of generating different types of vascular smooth muscle cells (SMCs) - the cells which make up the walls of blood vessels - using cells from patients' skin. This work could lead to new treatments and better scre ... more
Drug shown to reverse radioiodine resistance in some advanced thyroid cancers
The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center. Published in the issue of the New England Jo ... more
Public-private collaboration launches to tackle antibiotic research
GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barrier ... more
Galapagos’ service companies, BioFocus and Argenta, announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases. Under the terms of th ... more
We discover new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. We also focus on getting the bes ... more
AstraZeneca is a leading global pharmaceutical company with an extensive product portfolio spanning six major therapeutic areas: gastrointestinal, cardiovascular, infection, neuroscience, oncology, and respiratory. In Canada, AstraZeneca employs approximately 1,050 employees and its headqua ... more
What determines the stability of proteins?
With mathematical methods and computer simulations, Humboldt Fellow Richard Henchman (University of Manchester) is exploring the factors of protein stability – Research stay at the Heidelberg Institute for Theoretical Studies (HITS), supported by the Alexander von Humboldt foundation. Since ... more
Sweet news for stem cell's 'Holy Grail'
Scientists have used sugar-coated scaffolding to move a step closer to the routine use of stem cells in the clinic and unlock their huge potential to cure diseases from Alzheimer's to diabetes. The problem facing scientists is how to encourage stem cells to turn into the particular type of ... more
UK scientists have designed a high throughput method to determine the phenotypes of the different Escherichia coli strains that cause urinary tract infections. The method couples bacterial growth requirements to Fourier transform infrared spectroscopy. The majority of urinary tract infectio ... more
The University of Manchester is Britain's largest single-site university with a proud history of achievement and an ambitious agenda for the future. more
Medivir AB announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a ... more
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
Janssen Biologics announced it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK). Sirukumab is a human anti-interleukin (IL)-6 monoclonal antibody being studied for the treatment of adults with moderately to sev ... more
Public-private collaboration launches to tackle antibiotic research
GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barrier ... more
We are part of the world’s largest healthcare company, Johnson & Johnson, and enjoy an international reputation for pharmaceutical innovation and quality. For instance, EPREX™ , a breakthrough in the treatment of anaemia, has helped hundreds of thousands of patients and achieved sales of m ... more
A consortium of nine research centres has obtained the melon genome, a horticultural specie with high economic value around the world. It is the first time that a Spanish initiative that unites private and state-run centres has obtained the complete genome of a higher organism, in this case ... more
CSIC recovers part of the genome of 2 hunter-gatherer individuals from 7,000 years ago
A team of scientists, led by researcher Carles Lalueza-Fox from CSIC (Spanish National Research Council), has recovered - for the first time in history - part of the genome of two individuals living in the Mesolithic Period, 7000 years ago. Remains have been found at La Braña-Arintero site, ... more
Temperature controls the genetic message
A team of scientists at the CSIC has shown that temperature can play a critical role in the control of splicing. The team led by Josep Vilardell, ICREA scientist at the CSIC's Molecular Biology Institute of Barcelona, has demonstrated that temperature, through its effects on RNA structure, ... more
Consejo Superior De Investigaciones Científias (CSIC)
The Spanish National Research Council (CSIC) is the largest public institution dedicated to research in Spain and the third largest in Europe. Belonging to the Spanish Ministry of Science and Innovation through the Secretary of State for Research, its main objective is to develop and promot ... more
Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched
An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression. Novel Methods leading to N ... more
Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched
An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression. Novel Methods leading to N ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
